Skip to main content

Blog

Watch: Capricor Therapeutics – Regulatory Update & Clinical Insights on Deramiocel for Duchenne Cardiomyopathy

...

Sarepta to Resume ELEVIDYS Shipments to Ambulatory Patients After FDA Recommends Removal of Voluntary Hold for Ambulatory Population

...

FDA Grants Breakthrough Therapy Designation to Avidity’s del-zota

...

Update on ELEVIDYS Shipments in the U.S.

...

ELEVIDYS Update

...

Sarepta Therapeutics Announces Update on ELEVIDYS Label, Company Restructuring

...

Post AAV Gene Therapy Resources

...

Capricor Therapeutics Receives Complete Response Letter Regarding Deramiocel (CAP-1002)

...

Connecting with Experts via PPMD For You

...

Medicaid, Reconciliation Passage, and What Comes Next for Our Community

...